The Keynote 063 trial (NCT03019588) is comparing the efficacy of treatment with pembrolizumab vs. paclitaxel in Asian PD-L1+ patients with advanced GC who did not respond to any combination treatment containing a fluoropyrimidine and platinum agent. Here, CD274 is linked to gastric cancer.